Syneos Health 的 Oracle 云 ERP：构建面向未来创新的数字化核心 [PAN3880].pdf

《Syneos Health 的 Oracle 云 ERP：构建面向未来创新的数字化核心 [PAN3880].pdf》由会员分享，可在线阅读，更多相关《Syneos Health 的 Oracle 云 ERP：构建面向未来创新的数字化核心 [PAN3880].pdf（24页珍藏版）》请在三个皮匠报告上搜索。

1、Copyright 2025 Accenture.All rights reserved.Syneos Healths Oracle Cloud ERP:Building a Digital Core for Future InnovationVamsi AndavarapuPratish MenonManaging Director,Oracle H&PS Business Group Lead,AccentureDelivery Lead,Oracle Business Group,Accenture Pankaj GuptaFinance Lead,Oracle Business Gro

2、up,AccentureAdam TuckmanSenior Vice President,Business Finance,Syneos HealthGareth HaleExecutive Director,Syneos HealthProgram highlightsUnmatched in scope.Unprecedented in impact.The largest CRO transformation.Live in July 2025 Live in July 2025 on Oracle Cloud ERP(Fusion):The next-generational AI-

3、ready digital back-office core for innovation MultiMulti-cloud implementation cloud implementation with best of breed capabilities 30+systems retired 30+systems retired-3 modern cloud back-office platforms 28,000+users,global deployment 28,000+users,global deployment across Americas,EMEA&APAC,unifie

4、d data and processes,unified data and processes Harnessing Oracle Clouds AIOracle Clouds AI-driven automation driven automation and Redwood UX adoption Redwood UX adoption for transformative enterprise solutions92%89%96%SyneosSyneos Health Health has helped to develop or commercialize 93%of novel dr

5、ugs approved by the FDA in the last five years(2020-2024).SyneosSyneos Health Health has helped to develop or commercialize 90%of products granted marketing authorization by the European Medicines Agency(EMA)in the last five years(2020-2024).OncologyGeneral MedicineNon-oncology and non-CNSCentral Ne

6、rvous System(CNS)93%Novel drugs approved by the FDAOncologyGeneral MedicineNon-oncology and non-CNSCentral Nervous System(CNS)90%Novel drugs approved by the EMA93%83%89%Global reach in allmajor geographiesTherapeutic expertise in all major categories480+medical doctors(MDs)and 750+doctors of philoso